Navigation Links
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Date:12/3/2007

luding cellular growth, increased cell movement and invasion, and an increased ability of cancer cells to metastasize. Other observations have implicated cMET in increased angiogenesis. Studies of tumors in humans have associated cMET with more aggressive forms of cancer, such as lung and renal cancer, and activating cMET mutations have been observed in a wide range of other cancer types including colon, prostate, and gastric cancers.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and cMET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, the potential of SGX523 as a treatment for certain cancers, the outcome of FDA review of the SGX523 IND submission, timing of commencement of clinical studies and the ability of the company to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization. The results of early preclinical studies or clinical trials may not be p
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... mortality reductions; more funding needed for continued success , ... ... the World Health Organization,s World Malaria Report 2009 ... countries included in the study have witnessed reduction in malaria cases ... report, which compiles information gathered from malaria programs in 108 countries, ...
(Date:12/17/2009)... Pacific Shore Holdings, Inc., ... today announced the launch of their new Thermal-Aid ... packs are specifically designed to reduce swelling and ... variety of applications. Researchers behind Thermal-Aid created a ... to hold temperatures for long periods of time, ...
(Date:12/17/2009)... ,Hopenhagen, the city is calling itself, ... international conference on climate change. Narconon has its ... of the worldwide Narconon drug education ... from climate change. But the streets thrum with ... by with flashing blue lights - a youth ...
(Date:12/17/2009)... the stage at the Fisher Theatre on Dec. 17 for the ... cancer survivors will be the real stars of the show. , ... ... cast takes the stage at the Fisher Theatre on Dec. 17 ... Beaumont cancer patients and cancer survivors will be the real ...
(Date:12/17/2009)... now able to access trusted medical information using virtually any ... ... (PRWEB) December 17, 2009 -- Skyscape, Inc., the world’s most ... the Internet, has launched a mobile clinical decision application on ... now available on most smart phone devices, making the ability ...
Breaking Medicine News(10 mins):Health News:WHO World Malaria Report Shows Aid Efforts Are Working 2Health News:WHO World Malaria Report Shows Aid Efforts Are Working 3Health News:Thermal-Aid Bears Provide Warm Comfort to Children at Penny Lane for the Holidays 2Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4
... Radiology Support Devices,(RSD), a global leader of anthropomorphic ... Nuclear Medicine announced its new,Breathing Phantom designed for ... meeting., "We are very pleased to unveil ... said Matthew Alderson, President of RSD. "Ultimately,patients will ...
... Available in Three Gorgeous Tints!, SAN JOSE, Calif., ... http://www.janmarini.com ) today announced the addition of two,new colors ... Face,Protectant SPF 30 with PhytoMelanin. The sunscreen widely recommended ... any skin tone., Jan Marini,s original tinted shade, ...
... Dec. 10 Sen. Max Baucus,(D-Mont.), chair of ... leadership on a must-pass Medicare bill this year. ... committee last week,but with Congress, scheduled adjournment coming ... Rangel (D-N.Y.), chair of the House Ways &,Means ...
... can lead to both longer hospital stays and more ... studies from Purdue University. , "Americans are overweight, and ... obesity," said Ken Ferraro, a professor of sociology. "However, ... to get younger, we wanted to know how living ...
... -- Mayo Clinic researchers today presented results of ... -- a first step therapy designed to reduce ... dexamethasone (Cybor-D) showing an improved response over the ... by Craig B. Reeder, M.D., at the American ...
... research in the December issue of Preventive Medicine, published ... access to cigarettes from commercial venues from 2000 to ... Cohort study, a longitudinal telephone survey of youth less ... as young as 12 years of age buying cigarettes ...
Other Medicine News:Health News:Radiology Support Devices Introduces New Breathing Phantom System 2Health News:Jan Marini Skin Research Adds Two New Sheer Colors to Antioxidant Daily Face Protectant SPF 30 With PhytoMelanin(TM) 2Health News:NCPA Statement Urging Congress to Include Pharmacy Provisions in Medicare-Medicaid Legislation 2Health News:Living longer with obesity means heavier burden for hospitals 2Health News:Living longer with obesity means heavier burden for hospitals 3
(Date:12/17/2009)... Mass., Dec. 17 Just how much ... much and how do those working with patients ... protect themselves from over exposure? Veteran-owned RADeCO Health, ... announced the launch of the RADView(TM) CT dosimeter, ... radiation exposures from Computed Tomography (CT) scans of ...
(Date:12/17/2009)... Fraternal Order of Police help Easter Seals New ... PORT JERVIS, N.Y., Dec. 17 On ... Fraternal Order of Police and dozens of volunteers ... Development Center, Project Discovery, in Port Jervis, to ... need. Hundreds of local families attended the Community ...
(Date:12/17/2009)... 17 CANTEL MEDICAL CORP. (NYSE: ... of Directors intends to pay, for the first time, ... or $0.10 per share annually, on the Company,s common ... $0.05 per share of outstanding common stock, to be ... at the close of business on January 15, 2010. ...
Breaking Medicine Technology:Revolutionary Radiation Monitoring Device for CT Scans 2Revolutionary Radiation Monitoring Device for CT Scans 3CVS/pharmacy and the New York State Fraternal Order of Police Help Families in Port Jervis Have a Merry and Memorable Holiday Season 2Cantel Medical Authorizes Semiannual Dividend 2Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 1Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 2Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 3Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 4Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 1Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 2Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 3Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 4Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 5Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 6Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 49558 1Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 49558 2
... Independent Study by the National Cancer Institute Revealed Divine No. ... in Inhibiting Viruses that Cause ... and Anal Cancers in vitro, ORLANDO, Fla., Jan. 22 ... that promises to,revolutionize the market. The National Cancer Institute,s Laboratory ...
... access to effective health solutions in ... developing countries, ... today that Dr. Rajeev Venkayya has joined the Global Health,Program as ... former coordinator of U.S. government medical and public health,efforts, including preparations ...
Other Medicine Technology:Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute 2Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery 2
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Curved shafts with 70 degree angled 3 mm tips. Flat, cross action handle with dull finish. Most popular size or model....
Round handle forceps with delicate angled 9 mm jaws. A small groove on the interior portion of the platform is aligned with the handle and provides additional control of trailing haptic during insert...
Two rows of teeth on jaws provide a firm purchase on the nucleus fragment for removal. Flat handle with dull finish....
Medicine Products: